United Therapeutics Corp
UTHR
$513.12
-1.51%
United Therapeutics Corp is a biotechnology company focused on developing and commercializing innovative therapies for pulmonary arterial hypertension (PAH), a rare and progressive disease, with a portfolio that includes Tyvaso DPI, Remodulin, Orenitram, Adcirca, and Unituxin. The company is a market leader in the PAH space, leveraging its expertise in the prostacyclin pathway to maintain a strong competitive position. Currently, the stock is drawing attention due to positive Phase 3 data for Tyvaso in a new lung disease indication, which could significantly expand its market opportunity, alongside ongoing debates about pipeline sustainability and pricing pressures.…
UTHR
United Therapeutics Corp
$513.12
Related headlines
Investment Opinion: Should I buy UTHR Today?
Rating: Buy. The thesis is that UTHR's dominant position in PAH, exceptional margins, and the upcoming Tyvaso expansion into a new lung disease indication provide a strong growth catalyst, while the stock trades at a discount to peers. The consensus recommendation is Buy with an average target of $664.33, implying 29.5% upside.
Sign up to view all
UTHR 12-Month Price Forecast
The AI assessment leans bullish, driven by UTHR's exceptional profitability and the potential for Tyvaso's new indication to reaccelerate growth. However, the recent revenue decline and forward PE above trailing PE temper confidence, making the stance moderately bullish. Key developments to watch include FDA approval timing, quarterly revenue trends, and competitive dynamics. An upgrade to high confidence would require evidence of sustained revenue growth, while a downgrade would follow a failed approval or significant margin erosion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $664.33 and implied upside of +29.5% versus the current price.
Average Target
$664.33
0 analysts
Implied Upside
+29.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$515 - $725
Analyst target range
With 12 analysts covering the stock, the consensus recommendation is 'Buy' (mean score of 1.64), with 10 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The average target price is $664.33, implying a substantial 29.5% upside from the current price of $513.12. The target range spans from $515.00 (low) to $725.00 (high), with the low target barely above the current price, suggesting limited downside risk according to the most bearish analyst. The high target of $725 assumes successful FDA approval and commercial launch of Tyvaso for the new indication, which could drive significant revenue growth, while the low target likely reflects concerns about competitive pressures or pipeline setbacks. Recent ratings actions have been mixed, with Wells Fargo upgrading to Overweight in May 2026, while B of A maintained Neutral, indicating some divergence in sentiment but overall a bullish tilt.
Bulls vs Bears: UTHR Investment Factors
United Therapeutics presents a compelling bull case driven by exceptional profitability, a strong balance sheet, and a promising new indication for Tyvaso that could unlock significant growth. The stock trades at a discount to peers on a PE basis, and analysts see nearly 30% upside. However, the recent revenue decline and concentration risk in Tyvaso temper enthusiasm, while the forward PE suggests the market is cautious about earnings sustainability. The central tension is whether Tyvaso's new indication can reignite growth and offset the core franchise's maturation—if successful, the stock could re-rate higher; if not, the current valuation may already reflect peak earnings. Overall, the bull case currently has stronger evidence, given the analyst consensus and margin strength, but the revenue trajectory is the key factor to monitor.
Bullish
- Analyst consensus Buy with 29.5% upside: 12 analysts rate UTHR a Buy (mean 1.64), with an average target of $664.33, implying 29.5% upside from the current $513.12. The high target of $725 suggests even greater potential if Tyvaso's new indication succeeds.
- Exceptional profitability and margins: Gross margin is 87.92% and operating margin is 47.67% (TTM), far above industry averages. Net margin of 41.94% (TTM) demonstrates strong pricing power and operational efficiency, supporting a premium valuation.
- Tyvaso Phase 3 data opens new market: Positive Phase 3 results for Tyvaso in a new lung disease indication (reported March 2026) could significantly expand the addressable market. This catalyst drove the stock's 65.17% one-year gain and underpins the high analyst targets.
- Low debt and strong balance sheet: Debt-to-equity is just 0.0053, and the current ratio is 6.60, indicating minimal financial risk. This financial flexibility supports continued R&D investment and potential M&A.
Bearish
- Revenue declined 1.62% YoY in Q1 2026: Q1 2026 revenue of $781.5M fell from $794.4M a year ago, breaking a growth streak. Tyvaso sales dropped $13.4M, indicating potential market saturation or competitive pressure in the core PAH franchise.
- Forward PE higher than trailing PE: Forward PE of 17.08x exceeds trailing 16.17x, implying the market expects earnings to decline. This is unusual for a growth stock and suggests conservative estimates or anticipated margin compression.
- Recent price momentum has stalled: The stock is down 9.73% over the past 3 months and 2.65% over the past month, underperforming the S&P 500. It sits at 84.2% of its 52-week range, leaving limited near-term upside without a new catalyst.
- Concentration risk in Tyvaso: Tyvaso accounts for 58.5% of total revenue ($457.5M of $781.5M). Any setback in this product—such as a competitor or pricing pressure—would disproportionately impact the company's financials.
UTHR Technical Analysis
United Therapeutics has demonstrated a robust long-term uptrend, with the stock price surging 65.17% over the past year, significantly outperforming the S&P 500's 20.48% gain. Currently trading at $513.12, the stock is positioned at 84.2% of its 52-week range (between $302.19 low and $609.35 high), indicating it remains near the upper end of its historical band, which typically reflects strong momentum but also potential overextension. The stock's beta of 0.564 suggests it is less volatile than the broader market, providing some cushion during pullbacks.
Beta
0.56
0.56x market volatility
Max Drawdown
-16.3%
Largest decline past year
52-Week Range
$302-$609
Price range past year
Annual Return
+65.2%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | +3.6% |
| 3m | -9.7% | +2.7% |
| 6m | +8.4% | +11.4% |
| 1y | +65.2% | +18.7% |
| ytd | +3.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
Revenue in Q1 2026 was $781.5 million, a slight decline of 1.62% year-over-year, breaking a streak of sequential growth seen in 2025 (Q2: $798.6M, Q3: $799.5M, Q4: $790.2M). The revenue dip is primarily due to a $13.4 million decrease in Tyvaso sales, which remains the dominant product at $457.5 million, while Orenitram and Remodulin contributed $135.6 million and $126.6 million, respectively. Despite the revenue decline, the company's gross margin remains exceptionally high at 82.93%, and net income of $274.9 million in Q1 2026 reflects a net margin of 35.18%, down from 46.10% in Q4 2025 but still robust. Operating margin stood at 41.69%, indicating strong operational efficiency, though slightly compressed from the 45.24% in Q4 2025.
Quarterly Revenue
$781500000.0B
2026-03
Revenue YoY Growth
-1.6%
YoY Comparison
Gross Margin
82.9%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Given positive net income, the PE ratio is the primary valuation metric. The trailing PE is 16.17x, while the forward PE is 17.08x, suggesting the market expects earnings to grow modestly, with the forward multiple slightly higher, implying a potential earnings decline or conservative estimates. The PEG ratio of 1.16 indicates the stock is reasonably priced relative to its growth rate, which is typical for a mature biotech. Compared to the industry average PE of 22x (from valuation data), UTHR trades at a 26.5% discount, which is notable given its superior gross margin of 87.92% and operating margin of 47.67%, suggesting the market may be underpricing its profitability. Historically, the stock's PE has ranged from 8.75x (Q1 2024) to 24.44x (Q2 2022), with the current 16.17x sitting near the middle, indicating it is not at extreme valuation levels, but the recent price surge has pushed it above the 2025 average of around 13x.
PE
16.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but manageable. The company's debt-to-equity is negligible at 0.0053, and the current ratio of 6.60 indicates ample liquidity. However, revenue declined 1.62% YoY in Q1 2026, and net margin compressed from 46.10% in Q4 2025 to 35.18% in Q1 2026, suggesting potential margin pressure. The heavy reliance on Tyvaso (58.5% of revenue) creates concentration risk; a decline in Tyvaso sales, as seen in Q1, could significantly impact overall financial performance. Free cash flow remains positive at $1.02B TTM, but the forward PE exceeding trailing PE hints at expected earnings contraction, which could pressure the stock if realized.
FAQ
The key risks are: 1) Revenue concentration in Tyvaso, which accounts for 58.5% of sales; a decline in Tyvaso could significantly hurt earnings. 2) Regulatory and clinical risks: the FDA could delay or reject the new Tyvaso indication, as seen in the bear case. 3) Competitive pressures from other PAH therapies could erode market share. 4) Macro risks: although beta is low, a broader market downturn could still affect the stock. The most severe risk is a failure of Tyvaso's expansion, which could lead to a re-rating and a drop toward the 52-week low of $302.19, a potential -41% downside from current levels.
The 12-month forecast is moderately bullish, with a base case probability of 50% targeting $600-$664, a bull case (30%) targeting $664-$725, and a bear case (20%) targeting $515-$550. The base case assumes FDA approval of Tyvaso's new indication with a moderate launch, leading to stable revenue and margins. The bull case requires faster-than-expected adoption, while the bear case involves delays or competitive setbacks. The average analyst target of $664.33 implies a 29.5% upside, and the consensus rating is Buy. The most likely scenario is the base case, with the stock appreciating to around $664 over the next year.
UTHR is currently undervalued relative to its industry peers, with a trailing PE of 16.17x versus the industry average of 22x, a 26.5% discount. Its PS ratio of 6.78x and EV/EBITDA of 11.03x are also reasonable given its high margins. Historically, the stock's PE has ranged from 8.75x to 24.44x, and the current level is near the middle, suggesting it is not overvalued. The forward PE of 17.08x implies the market expects earnings to decline, which may be overly conservative. The market is pricing in modest growth and some risk, but the strong fundamentals and potential Tyvaso expansion suggest the stock could be undervalued.
UTHR is a good buy for investors with a medium-to-long-term horizon, given the 29.5% upside to the average analyst target of $664.33 and a trailing PE of 16.17x, which is below the industry average of 22x. The primary risk is the recent revenue decline, but the positive Phase 3 data for Tyvaso in a new indication provides a strong catalyst. For risk-averse investors, the low beta of 0.564 and strong balance sheet offer some protection. However, if you are seeking immediate growth, the current revenue stagnation may be a concern. Overall, it is a buy for those who believe in Tyvaso's expansion potential and can tolerate some near-term volatility.
UTHR is more suitable for long-term investment, given its low beta of 0.564, strong balance sheet, and the multi-year potential of Tyvaso's new indication. The stock has shown a 65% gain over the past year, but short-term momentum has stalled, with a 9.7% decline over the past three months. For short-term traders, the stock may offer opportunities around FDA approval news, but the low volatility and lack of immediate catalysts make it less ideal. A minimum holding period of 2-3 years is recommended to fully capture the potential of the Tyvaso expansion and the company's pipeline. The company pays no dividend, so returns will come from capital appreciation.